Drug targets and lipid biomarkers of hyperlipidemia associated diseases
Hyperlipidemia (HL) is characterized by elevated level of plasma lipids affecting regular functioning of lipid-protein interactions leading to disease. The traditional lipid biomarkers utilized for detection of individuals with HL and Cardiovascular Diseases (CVD) risk, sometimes fail to predict fut...
Main Authors: | Sneha Rai, Sonika Bhatnagar |
---|---|
Format: | Article |
Language: | English |
Published: |
Science Planet Inc.
2017-10-01
|
Series: | Canadian Journal of Biotechnology |
Online Access: | https://www.canadianjbiotech.com/CAN_J_BIOTECH/Archives/v1/Special Issue/cjb.2017-a16.pdf |
Similar Items
-
Impact of lipid-lowering drugs on lipid profile in hyperlipidemia patients
by: Khawla A Shemran, et al.
Published: (2023-01-01) -
Public Perspective on Hyperlipidemia Drugs and Sentiments About Hyperlipidemia on Twitter
by: Murojil Hasan, et al.
Published: (2023-08-01) -
Public Perspective on Hyperlipidemia Drugs and Sentiments About Hyperlipidemia on Twitter
by: Murojil Hasan, et al.
Published: (2023-08-01) -
Lipid peroxidation and antioxidants in hyperlipidemia and hypertension
by: PATRICIA MORIEL, et al.
Published: (2000-01-01) -
The association between hyperlipidemia, lipid-lowering drugs and diabetic peripheral neuropathy in patients with type 2 diabetes mellitus.
by: Kuo-Cheng Chang, et al.
Published: (2023-01-01)